These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Cancer Therapies and Vascular Toxicities. Meilhac A; Cautela J; Thuny F Curr Treat Options Oncol; 2022 Mar; 23(3):333-347. PubMed ID: 35244888 [TBL] [Abstract][Full Text] [Related]
24. Cardiotoxicity of cancer chemotherapy: implications for children. Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964 [TBL] [Abstract][Full Text] [Related]
25. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies. Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150 [TBL] [Abstract][Full Text] [Related]
26. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463 [TBL] [Abstract][Full Text] [Related]
27. From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. Tocchetti CG; Cadeddu C; Di Lisi D; Femminò S; Madonna R; Mele D; Monte I; Novo G; Penna C; Pepe A; Spallarossa P; Varricchi G; Zito C; Pagliaro P; Mercuro G Antioxid Redox Signal; 2019 Jun; 30(18):2110-2153. PubMed ID: 28398124 [No Abstract] [Full Text] [Related]
29. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Schmitz KH; Prosnitz RG; Schwartz AL; Carver JR Cancer; 2012 Apr; 118(8 Suppl):2270-6. PubMed ID: 22488701 [TBL] [Abstract][Full Text] [Related]
30. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696 [TBL] [Abstract][Full Text] [Related]
31. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110 [TBL] [Abstract][Full Text] [Related]
33. Cardio-oncology: management of cardiovascular toxicity. Markman TM; Markman M F1000Res; 2019; 8():. PubMed ID: 30755794 [TBL] [Abstract][Full Text] [Related]
34. Genetics of cancer therapy-associated cardiotoxicity. Kim Y; Seidman JG; Seidman CE J Mol Cell Cardiol; 2022 Jun; 167():85-91. PubMed ID: 35358500 [TBL] [Abstract][Full Text] [Related]
35. New progress in elucidating the relationship between cancer therapy and cardiovascular toxicity. Wu C; Lin D; Ma F; Jiang F; Wang Y Biosci Trends; 2021 Sep; 15(4):211-218. PubMed ID: 34305102 [TBL] [Abstract][Full Text] [Related]
36. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Doyno C; Sobieraj DM; Baker WL Clin Toxicol (Phila); 2021 Jan; 59(1):12-23. PubMed ID: 32960100 [TBL] [Abstract][Full Text] [Related]
37. Chemotherapy and Cardiotoxicity in Hematologic Malignancies. Stellitano A; Fedele R; Barilla S; Iaria A; Rao CM; Martino M Curr Cancer Drug Targets; 2017; 17(4):311-324. PubMed ID: 27903214 [TBL] [Abstract][Full Text] [Related]